Ausgelaufene Studien

In patients with evidence of device-detected sub-clinical atrial fibrillation (SCAF) and additional risk factors for stroke, treatment with apixaban compared with aspirin will reduce the risk of the composite of stroke and systemic embolism.

• Clinical atrial fibrillation documented by surface ECG  lasting ≥ 6 minutes, with or without clinical symptoms
• Mechanical valve prosthesis, recent (within past 6 months) deep vein thrombosis or pulmonary embolism or other condition requiring treatment with an anticoagulant
• Allergy to aspirin or apixaban
• Severe renal Serious bleeding in the last 6 months or at high risk of
• Moderate to severe hepatic impairment
• Ongoing need for combination therapy with aspirin and clopidogrel
• Meets criteria for requiring lower dose of apixaban AND also has ongoing need for strong inhibitors of both CYP3A4 and P-glycoprotein (e.g., ketoconazole, itraconazole, ritonavir or clarithromycin)
• Ongoing need for strong dual inducers of both CYP3A4 and P-glycoprotein
• Received an investigational drug in the past 30 days
• Participants considered by the investigator to be unsuitable for the study for any of the following reasons:
  • Not agreeable for treatment with either aspirin or apixaban or anticipated to have poor compliance on study drug treatment